{
  "docId": "019de072-a701-779d-b9c1-29622b36dd41",
  "docSlug": "f2c95dae10c304072442cd11deed84ec",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 53 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 17,
  "pageCount": 53,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-a701-779d-b9c1-29622b36dd41/17",
  "deckHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41",
  "deckJsonHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41.json",
  "deckAnchorHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.92,
        "x": 0.04,
        "y": 0.62
      },
      "kind": "list",
      "text": "Global Opto RX saw -5% reported revenue and -3% organic revenue decline. U.S. saw -14% reported/organic revenue decline. International saw 10% reported revenue growth and 16% organic revenue growth, driven by Europe. Vyzulta saw 44% TRx growth, driven by demand and increased coverage. Launched Xipere, a therapy that uses the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, in U.S.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40e72771-b6c1-4a83-91ea-7595219f3e80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.92,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "list",
      "text": "Global Surgical saw 7% reported revenue growth and 13% organic revenue growth, driven by increased demand and the backlog in procedures. Product growth was driven by an increase in capital equipment consumables. U.S.: 2% reported revenue growth and 4% organic revenue growth. International: 9% reported revenue growth and 17% organic revenue growth.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58e4df2a-f842-4d5b-b52e-2acfdd307414",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "Global Ophtho Rx",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a324481-3962-4bf2-b434-6e1c61043d1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.215
      },
      "kind": "paragraph",
      "text": "Global Surgical",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77e0a04c-c39b-4f2c-9dc5-9eef239e3309",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.26,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios. 2. IQVIA NPA monthly. 3. See footnote 2 at Slide 9 for further details regarding the realigned segment reporting structure and the conformed prior period presentation.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "500149fb-e3c9-48f0-ac50-75dd98963f39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.52,
        "x": 0.178,
        "y": 0.055
      },
      "kind": "title",
      "text": "Bausch + Lomb 1Q22 Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a675c45e-a427-43b2-bc14-059b999473c2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "485b919d-8090-46f2-ba6a-8e1ed6bcedf9",
      "evidence": "list/bullet: Global Opto RX saw -5% reported revenue and -3% organic revenue decline.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 19,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7720718b-ea2d-4109-9564-eb09c0194463",
      "evidence": "Financial results and leverage discussion",
      "position": 0,
      "objective": "Highlighting the need for strategic alternatives",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}